ASCO-GU 2025: CRB-701 (SYS6002) Demonstrates Encouraging Safety and Broader Efficacy in Ph 1 Study February 19, 2025
Positive updated data from THIO-101 pivotal Ph 2 trial of THIO + Libtayo in patients with advanced NSCLC who failed two or more SOC regimens announced February 11, 2025
Primary Endpoint Met in Ph 2b Trial of Zipalertinib in Patients with NSCLC with EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy February 5, 2025
BRAFTOVI Combination Regimen Significantly Improved PFS and OS in Ph 3 BREAKWATER Trial February 5, 2025
Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study of sirexatamab (DKN-01) Reported February 4, 2025
Positive Topline Results of Ph 3 COMPETE Trial with ITM-11 in Patients with Gr 1 or 2 GEP-NETs announced February 4, 2025
Positive interim Alpha DaRT data from multiple clinical trials in pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other clinical trials announced February 4, 2025
Positive topline results from the OS analysis of the Ph 3 INAVO120 study of Itovebi + Ibrance & fulvestrant for people with PIK3CA-mut HR+ve, HER2-neg endocrine-resistant, locally advanced or metastatic breast cancer announced February 4, 2025
Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer February 4, 2025
New Real-World DOR Data for JELMYTO Reports 68% RFS at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) January 28, 2025
ASCO GI 2025: Positive Updated Data from ASPEN-06 Ph 2 Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer presented January 28, 2025
FAILED TRIAL: Ph 3 LEAP-015 Trial of KEYTRUDA, LENVIMA, Chemo combo in Patients with HER2-neg Gastroesophageal Adenocarcinoma did not meet co-primary endpoint of OS January 28, 2025
Ph 2b Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma January 28, 2025
ASCO GI 2025: Encouraging Results from Ph 1b/2 STELLAR-001 Trial of Zanzalintinib +/- Immune Checkpoint Inhibitor in Metastatic CRC announced January 28, 2025
ASCO GI 2025: Results from CheckMate -8HW Analysis of Opdivo + Yervoy Compared to Opdivo Monotherapy in Patients with MSI-H or MMRD Metastatic CRC announced January 28, 2025
ASCO GI 2025: Latest Ph 1/2 Data on ATN-022 in Advanced/Metastatic Gastric Cancer Including an ORR of 42.9% presented January 28, 2025
ASCO GI 2025: Final Ph 2 Clinical Casdozokitug Combination Data in Patients with Metastatic HCC Presented January 28, 2025
ASCO GI 2025: Initial Ph 2 Data for Vilastobart (XTX101) in Combination with Atezolizumab in Patients with MSS CRC announced January 28, 2025
ASCO GI 2025: Preliminary Cohort A Data from Ph 2 ASCEND Trial of Certepetide with SOC Chemo in Metastatic Pancreatic Ductal Adenocarcinoma reported January 28, 2025
ASCO GI 2025: Results from Subgroup Analysis of Ph 3 CABINET Pivotal Study of Cabozantinib in Advanced Gastrointestinal NET announced January 28, 2025
ASCO GI 2025: Results from Ph 3 CALGB (Alliance) / SWOG 80702 Clinical Trial in CRC announced January 28, 2025
ASCO GI 2025: BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic CRC from the Ph 3 BREAKWATER trial January 28, 2025
Positive Topline Results for TIVDAK in the China Subpopulation of the Global Ph 3 innovaTV 301 Trial in Patients with Recurrent/Metastatic Cervical Cancer Announced January 21, 2025
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage CTCL January 21, 2025
